pipette
ESEspañol

An adjuvant for in vivo CAR-T therapy potentiation against solid tumors

Y. Sun, Y. Ma, T. Guan, Y. Yan, Y. Ming, X. Huang, Y. Luo, J. Cai, G. Ma, F. You, M. Qiu, J. Chen, Y. Xia

PreprintReal-world use

In the authors' words

In vivo CAR-T therapy offers rapid and controllable T-cell engineering but has yet to achieve durable efficacy against solid tumors. Rather than focusing solely on CAR-T cells, we harness the intact immune system via an in vivo CAR-T adjuvant (iCTA). Composed of aluminum-manganese hydrogel, iCTA can form a spatially confined antigenic and immunostimulatory niche in-situ. By coupling controlled antigen exposure with STING-type I interferon signaling, iCTA not only recruited and reactivated CAR-T cells, but engage the CAR-negative immunocytes with enhanced dendritic-cell antigen presentation and mobilized endogenous antigen-specific T-cell responses. Combined with mRNA-LNP-mediated in vivo CAR-T generation, a single administration of iCTA increased CAR+ T-cell abundance in draining lymph nodes and blood by 2-fold. It also increased T and NK cell infiltration, established an IFNgamma-enriched tumor microenvironment, and reduced exhaustion-associated T-cell states. iCTA improved tumor regression and survival, establishing an adjuvant strategy to enhance in vivo CAR-T therapy.

Main resultThe abstract does not state a limitation.

Appeared: Tuesday, November 3. bioRxiv. Preprint, not yet peer-reviewed.

DOI: 10.64898/2026.10.30.763005